Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis

YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival.

(2020) Taofeek Kunle Owonikoko et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

(2020) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

(2020) Ticiana Leal et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

(2020) Sarah B Goldberg et al.   LANCET ONCOLOGY

Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer

(2020) Jyoti Singh et al.   FOOD AND CHEMICAL TOXICOLOGY

Advancements in small cell lung cancer: the changing landscape following IMPOWER-133

(2019) Jose Pacheco et al.   Clinical Lung Cancer

1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

(2019) M Reck et al.   ANNALS OF ONCOLOGY

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

(2019) Neal E. Ready et al.   Journal of Thoracic Oncology

OA03.06 ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities

(2019) C. Gay et al.   Journal of Thoracic Oncology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Different distant metastasis patterns based on tumor size could be found in extensive-stage small cell lung cancer patients: a large, population-based SEER study

(2019) Jia Li et al.   PeerJ

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment advances in small cell lung cancer (SCLC)

(2017) Saiama N. Waqar et al.   PHARMACOLOGY & THERAPEUTICS

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials

(2017) Gideon M. Blumenthal et al.   JAMA Oncology

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Prognostic effect of liver metastasis in lung cancer patients with distant metastasis

(2016) Yijiu Ren et al.   Oncotarget

High-Grade Neuroendocrine Carcinoma with Bronchial Intraepithelial Tumor Spread

(2015) Hideaki Kojima et al.   Journal of Thoracic Oncology

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Small cell lung cancer: Where do we go from here?

(2014) Lauren Averett Byers et al.   CANCER

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer

(2012) Taofeek K. Owonikoko et al.   Journal of Thoracic Oncology

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

(2012) Charles M Rudin et al.   NATURE GENETICS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

Specific organ metastases and survival in small cell lung cancer

(2012) KENSUKE NAKAZAWA et al.   Oncology Letters

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

(2010) David Moher et al.   International Journal of Surgery

Detection of brain metastases from small cell lung cancer

(2008) Tatjana Seute et al.   CANCER